Zymeworks stock price target reaffirmed at $32 by Citizens
Citizens reiterated a Market Outperform rating and $32 price target for Zymeworks (ZYME), citing clinical data on ZW191 and a Roche licensing deal. The stock is up 59% year-over-year. Zymeworks has $627.5M in cash and is conducting a share buyback. Other analysts have raised price targets, with Jefferies at $52 and H.C. Wainwright at $55.
How this was made
The 30-second read
Why it matters
The reaffirmed target and new deals suggest a short‑term bullish bias, but investors should monitor trial progress and integration execution.
Market read
The news provides fresh material for traders focusing on biotech catalysts and could drive Zymeworks' share price higher.
What to watch
Potential dilution from the share buyback program and integration risk of Theravance.
Background
The piece is an analyst note summarizing recent corporate developments for Zymeworks, a NASDAQ‑listed biotech.
Ticker impact
Citizens reaffirmed a $32 price target for Zymeworks after reporting a licensing deal with Roche and the completion of the Theravance Biopharma acquisition.
likely upward pressure as market prices in the new cash flow and milestone potential.
The article discloses fresh commercial agreements and a strategic acquisition, both of which are material for a biotech with a $28 share price.
Market effects
Strengthens the biotech sector's outlook on antibody‑drug conjugates and licensing partnerships.
Positive for North American biotech equities.
Highlights continued interest from large pharma in niche oncology assets.
Counterpoint
The licensing milestones may be priced in already; execution risk on Phase 1b could temper upside.
Key entities
- companyZymeworks Inc.
Biotech firm developing antibody‑drug conjugates.
- companyRoche
Pharma partner licensing ZW209.
- companyTheravance Biopharma
Acquired by Zymeworks.
